(Note: Immediately after this offering, Biofrontera AG, our parent company and sole existing stockholder immediately prior to this offering, will own approximately 72.7% of our outstanding shares of common stock. As a result, we expect to remain a “controlled company” within the meaning of NASDAQ’s corporate governance standards.)
We are a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, in particular, diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Our licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. We also market a topical antibiotic for treatment of impetigo, a bacterial skin infection.
Our principal licensed product is Ameluz®, which is a prescription drug approved for use in combination with our licensor’s medical device, which has been approved by the U.S. Food and Drug Administration (the “FDA”), the BF-RhodoLED® lamp, for photodynamic therapy, or PDT (when used together, “Ameluz® PDT”) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Our second prescription drug licensed product in our portfolio is Xepi® (ozenoxacin cream, 1%), a topical non-fluorinated quinolone that inhibits bacterial growth. Currently, no antibiotic resistance against Xepi® is known and it has been specifically approved by the FDA for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes. It is approved for use in adults and children 2 months and older. We are currently selling Xepi® for this indication in the United States under an exclusive license and supply agreement, or Xepi LSA, with Ferrer that was assumed by Biofrontera on March 25, 2019 through our acquisition of Cutanea.
Note: We were formed in March 2015 as Biofrontera Inc., a Delaware corporation, and a wholly-owned subsidiary of Biofrontera AG. Our Chairman and Chief Executive Officer is Professor Hermann Lübbert Ph.D. Prof. Dr. Lübbert founded Biofrontera AG in 1997 and has been managing the Company ever since.
(Note: The pricing date of Biofrontera’s IPO is TBA; the deal was tentatively scheduled for pricing on Wednesday night, Oct. 20, 2021.)
|Address||120 Presidential Way, Suite 330 Woburn, MA 01801|
|View Prospectus:||BIOFRONTERA INC.|
|Revenues||$22.42 mil (last 12 months)|
|Net Income||$-10.37 mil (last 12 months)|
|Price range||$5.00 - $7.00|
|Est. $ Volume||$18.0 mil|
|Manager / Joint Managers||Roth Capital Partners/ The Benchmark Company|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|